Overcome the challenges of PMS2 variant calling with Devyser LynchFAP – our new NGS solution
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Devyser and Thermo Fisher Scientific have agreed to expand commercial collaboration by including...
Bioiatriki is a leading medical laboratory in Greece, providing a range of prenatal genetic testing...
Devyser’s novel test for detecting donor-derived cell-free DNA in blood samples from...
The American College of Medical Genetics and Genomics (ACMG) has released an updated position...
A better patient care is the final objective for Dr. Helena Devos and the team at Sint Jan’s...
Devyser has inaugurated its CLIA-certified laboratory in Atlanta, Georgia. The laboratory will...
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA...
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...